

L Darryl Quarles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4829068/publications.pdf>

Version: 2024-02-01

169
papers

16,052
citations

15466

65
h-index

16605

123
g-index

177
all docs

177
docs citations

177
times ranked

11535
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. <i>Nature Genetics</i> , 2006, 38, 1310-1315.	9.4	1,063
2	Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: An in vitro model of osteoblast development. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 683-692.	3.1	842
3	Rapid Loss of Vertebral Mineral Density after Renal Transplantation. <i>New England Journal of Medicine</i> , 1991, 325, 544-550.	13.9	622
4	Fibroblast Growth Factor 23 Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1305-1315.	3.0	584
5	Regulation and Function of the FGF23/Klotho Endocrine Pathways. <i>Physiological Reviews</i> , 2012, 92, 131-155.	13.1	471
6	Pathogenic role of Fgf23 in Hyp mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E38-E49.	1.8	457
7	Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX. <i>Journal of Biological Chemistry</i> , 2003, 278, 37419-37426.	1.6	453
8	Endocrine functions of bone in mineral metabolism regulation. <i>Journal of Clinical Investigation</i> , 2008, 118, 3820-3828.	3.9	406
9	How Fibroblast Growth Factor 23 Works. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1637-1647.	3.0	355
10	Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1227-1234.	3.1	323
11	Hemodialysis-associated subclavian vein stenosis. <i>Kidney International</i> , 1988, 33, 1156-1159.	2.6	295
12	FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 285, E1-E9.	1.8	292
13	Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. <i>Kidney International</i> , 2005, 67, 760-771.	2.6	290
14	Identification of a Novel Extracellular Cation-sensing G-protein-coupled Receptor. <i>Journal of Biological Chemistry</i> , 2005, 280, 40201-40209.	1.6	271
15	The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 575-583.	3.0	245
16	Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2116-2124.	3.0	241
17	Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. <i>Kidney International</i> , 1994, 45, 1710-1721.	2.6	230
18	Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease. <i>Experimental Cell Research</i> , 2012, 318, 1040-1048.	1.2	229

#	ARTICLE	IF	CITATIONS
19	Bone proteins PHEX and DMP1 regulate fibroblastic growth factor <i>Fgf23</i> expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. <i>FASEB Journal</i> , 2011, 25, 2551-2562.	0.2	228
20	Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. <i>Nature Reviews Endocrinology</i> , 2012, 8, 276-286.	4.3	225
21	GPRC6A Null Mice Exhibit Osteopenia, Feminization and Metabolic Syndrome. <i>PLoS ONE</i> , 2008, 3, e3858.	1.1	215
22	Association of Body Mass Index with Outcomes in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2088-2096.	3.0	196
23	GPRC6A mediates responses to osteocalcin in $\hat{1}^2$ -cells in vitro and pancreas in vivo. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1680-1683.	3.1	194
24	Joint mouse-human phenome-wide association to test gene function and disease risk. <i>Nature Communications</i> , 2016, 7, 10464.	5.8	190
25	Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2013, 159, 233.	2.0	182
26	Cholecalciferol Supplementation Alters Calcitriol-Responsive Monocyte Proteins and Decreases Inflammatory Cytokines in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 353-361.	3.0	168
27	A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model. <i>PLoS ONE</i> , 2012, 7, e44161.	1.1	164
28	GPRC6A Mediates the Non-genomic Effects of Steroids. <i>Journal of Biological Chemistry</i> , 2010, 285, 39953-39964.	1.6	163
29	Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. <i>Journal of Clinical Investigation</i> , 2003, 111, 1029-1037.	3.9	138
30	Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 110-116.	2.2	136
31	Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 658-664.	2.2	135
32	Musculoskeletal Complications After Renal Transplantation: Pathogenesis and Treatment. <i>American Journal of Kidney Diseases</i> , 1992, 19, 99-120.	2.1	134
33	FGFR3 and FGFR4 Do not Mediate Renal Effects of FGF23. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2342-2350.	3.0	123
34	PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Role of Fibroblast Growth Factor 23 in Phosphate Homeostasis and Pathogenesis of Disordered Mineral Metabolism in Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2007, 20, 302-308.	0.7	122
35	Calcium Regulates FGF-23 Expression in Bone. <i>Endocrinology</i> , 2013, 154, 4469-4482.	1.4	115
36	Conditional deletion of <i>Pkd1</i> in osteocytes disrupts skeletal mechanosensing in mice. <i>FASEB Journal</i> , 2011, 25, 2418-2432.	0.2	110

#	ARTICLE	IF	CITATIONS
37	Cloning and Sequencing of Human PEX from a Bone cDNA Library: Evidence for Its Developmental Stage-Specific Regulation in Osteoblasts. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1009-1017.	3.1	108
38	Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 329-335.	1.0	105
39	A Distinct Cation-Sensing Mechanism in MC3T3-E1 Osteoblasts Functionally Related to the Calcium Receptor. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 393-402.	3.1	104
40	Inhibition of MEPE cleavage by Phex. <i>Biochemical and Biophysical Research Communications</i> , 2002, 297, 38-45.	1.0	103
41	Evidence for a bone-kidney axis regulating phosphate homeostasis. <i>Journal of Clinical Investigation</i> , 2003, 112, 642-646.	3.9	102
42	Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development. <i>Current Medicinal Chemistry</i> , 2021, 28, 1489-1507.	1.2	101
43	Rickets in Cation-Sensing Receptor-Deficient Mice: An Unexpected Skeletal Phenotype. <i>Endocrinology</i> , 2001, 142, 3996-4005.	1.4	96
44	Calcium-Sensing Receptor Activation of Rho Involves Filamin and Rho-Guanine Nucleotide Exchange Factor. <i>Endocrinology</i> , 2002, 143, 3830-3838.	1.4	95
45	Impaired kidney growth in low-birth-weight children: Distinct effects of maturity and weight for gestational age. <i>Kidney International</i> , 2005, 68, 731-740.	2.6	95
46	Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 307-316.	1.2	93
47	Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. <i>Kidney International</i> , 2000, 57, 282-292.	2.6	92
48	Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 38-46.	3.1	92
49	Aluminum-Induced DNA synthesis in osteoblasts: Mediation by a G-protein coupled cation sensing mechanism. <i>Journal of Cellular Biochemistry</i> , 1994, 56, 106-117.	1.2	87
50	Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E508-E517.	1.8	87
51	Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. <i>Journal of Cell Science</i> , 2012, 125, 1945-57.	1.2	86
52	Overexpression of Phex in Osteoblasts Fails to Rescue the Hyp Mouse Phenotype. <i>Journal of Biological Chemistry</i> , 2002, 277, 3686-3697.	1.6	83
53	Multiligand Specificity and Wide Tissue Expression of GPRC6A Reveals New Endocrine Networks. <i>Endocrinology</i> , 2012, 153, 2062-2069.	1.4	83
54	Cation Sensing Receptors in Bone: A Novel Paradigm for Regulating Bone Remodeling?. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1971-1974.	3.1	81

#	ARTICLE	IF	CITATIONS
55	A Novel Cation-Sensing Mechanism in Osteoblasts Is a Molecular Target for Strontium. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 862-869.	3.1	81
56	Role of Matrix Extracellular Phosphoglycoprotein in the Pathogenesis of X-Linked Hypophosphatemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1645-1653.	3.0	81
57	Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in <i>hyp</i> mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E1636-E1644.	1.8	81
58	Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. <i>Journal of Endocrinology</i> , 2007, 192, 261-267.	1.2	80
59	Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. <i>Journal of Nutritional Biochemistry</i> , 2003, 14, 342-349.	1.9	76
60	Molecular to pharmacologic control of osteoblast proliferation and differentiation. <i>Journal of Cellular Biochemistry</i> , 1994, 55, 310-320.	1.2	73
61	β -Arrestin- and G Protein Receptor Kinase-Mediated Calcium-Sensing Receptor Desensitization. <i>Molecular Endocrinology</i> , 2005, 19, 1078-1087.	3.7	72
62	GPRC6A regulates prostate cancer progression. <i>Prostate</i> , 2012, 72, 399-409.	1.2	69
63	Antiandrogen Gold Nanoparticles Dual-Target and Overcome Treatment Resistance in Hormone-Insensitive Prostate Cancer Cells. <i>Bioconjugate Chemistry</i> , 2012, 23, 1507-1512.	1.8	68
64	Failure to Detect the Extracellular Calcium-Sensing Receptor (CasR) in Human Osteoblast Cell Lines. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1310-1319.	3.1	67
65	GPRC6A Mediates the Effects of L-Arginine on Insulin Secretion in Mouse Pancreatic Islets. <i>Endocrinology</i> , 2012, 153, 4608-4615.	1.4	67
66	GPRC6A: Jack of all metabolism (or master of none). <i>Molecular Metabolism</i> , 2017, 6, 185-193.	3.0	67
67	Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. <i>Journal of Clinical Investigation</i> , 2003, 111, 1029-1037.	3.9	67
68	Dose-Dependent Effects of <i>Runx2</i> on Bone Development. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1889-1904.	3.1	66
69	Evidence for a bone-kidney axis regulating phosphate homeostasis. <i>Journal of Clinical Investigation</i> , 2003, 112, 642-646.	3.9	66
70	Staphylococcus Aureus Bacteremia in Patients on Chronic Hemodialysis. <i>American Journal of Kidney Diseases</i> , 1985, 6, 412-419.	2.1	63
71	Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. <i>Kidney International</i> , 1996, 50, 1663-1671.	2.6	63
72	Polycystin-1 Regulates Skeletogenesis through Stimulation of the Osteoblast-specific Transcription Factor RUNX2-II. <i>Journal of Biological Chemistry</i> , 2008, 283, 12624-12634.	1.6	61

#	ARTICLE	IF	CITATIONS
73	Conditional Disruption of Pkd1 in Osteoblasts Results in Osteopenia Due to Direct Impairment of Bone Formation. <i>Journal of Biological Chemistry</i> , 2010, 285, 1177-1187.	1.6	61
74	Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. <i>Kidney International</i> , 1988, 34, 840-844.	2.6	57
75	Aluminum-Induced Mitogenesis in MC3T3-E1 Osteoblasts: Potential Mechanism Underlying Neosteogenesis*. <i>Endocrinology</i> , 1991, 128, 3144-3151.	1.4	57
76	Pathophysiology of X-Linked Hypophosphatemia, Tumor-Induced Osteomalacia, and Autosomal Dominant Hypophosphatemia: A PerPHEXing Problem. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 494-496.	1.8	57
77	FGF23 from bench to bedside. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F1168-F1174.	1.3	56
78	Conditional Deletion of Fgfr1 in the Proximal and Distal Tubule Identifies Distinct Roles in Phosphate and Calcium Transport. <i>PLoS ONE</i> , 2016, 11, e0147845.	1.1	56
79	Late Vascular Complications of the Subclavian Dialysis Catheter. <i>American Journal of Kidney Diseases</i> , 1986, 7, 225-228.	2.1	55
80	An experimental canine model of osteonecrosis: Characterization of the repair process. <i>Journal of Orthopaedic Research</i> , 1993, 11, 350-357.	1.2	54
81	The hypoxia-inducible factor-1 α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. <i>Bone Research</i> , 2016, 4, 16011.	5.4	54
82	Spectrum of disease in familial focal and segmental glomerulosclerosis. <i>Kidney International</i> , 1999, 56, 1863-1871.	2.6	53
83	Coordinated Maturation Regulation of PHEX and Renal Phosphate Transport Inhibitory Activity: Evidence for the Pathophysiological Role of PHEX in X-Linked Hypophosphatemia. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 2027-2035.	3.1	52
84	Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. <i>Molecular Endocrinology</i> , 2015, 29, 1759-1773.	3.7	52
85	FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 138, 66-74.	0.9	50
86	Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 349-355.	1.0	49
87	Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. <i>Nature Clinical Practice Nephrology</i> , 2009, 5, 24-33.	2.0	49
88	Novel Bone Endocrine Networks Integrating Mineral and Energy Metabolism. <i>Current Osteoporosis Reports</i> , 2013, 11, 391-399.	1.5	49
89	Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis. <i>Journal of Clinical Investigation</i> , 2017, 128, 157-174.	3.9	49
90	Inhibition of adipocyte differentiation by phytoestrogen genistein through a potential downregulation of extracellular signal-regulated kinases 1/2 activity. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 1853-1864.	1.2	48

#	ARTICLE	IF	CITATIONS
91	CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 90.	3.5	47
92	Role of serum in the developmental expression of alkaline phosphatase in MC3T3-E1 osteoblasts. <i>Journal of Cellular Physiology</i> , 1994, 158, 467-475.	2.0	46
93	Membrane and Integrative Nuclear Fibroblastic Growth Factor Receptor (FGFR) Regulation of FGF-23. <i>Journal of Biological Chemistry</i> , 2015, 290, 10447-10459.	1.6	46
94	Impaired osteoblast function in <i>GPRC6A</i> null mice. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 1092-1102.	3.1	44
95	Effect of asymmetric dimethylarginine on osteoblastic differentiation. <i>Kidney International</i> , 2001, 60, 1699-1704.	2.6	43
96	IRES-dependent translational control of <i>Cbfa1/Runx2</i> expression. <i>Journal of Cellular Biochemistry</i> , 2003, 88, 493-505.	1.2	43
97	<i>Kif3a</i> Deficiency Reverses the Skeletal Abnormalities in <i>Pkd1</i> Deficient Mice by Restoring the Balance Between Osteogenesis and Adipogenesis. <i>PLoS ONE</i> , 2010, 5, e15240.	1.1	42
98	Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II. <i>Scientific Reports</i> , 2018, 8, 12398.	1.6	41
99	'Dem bones' are made for more than walking. <i>Nature Medicine</i> , 2011, 17, 428-430.	15.2	40
100	Fibroblast growth factor 23 and <i>Klotho</i> co-dependent and independent functions. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 16-25.	1.0	38
101	Assessment of 24,25(OH) ₂ D levels does not support FGF23-mediated catabolism of vitamin D metabolites. <i>Kidney International</i> , 2012, 82, 1061-1070.	2.6	36
102	Aluminum-induced neo-osteogenesis: A generalized process affecting trabecular networking in the axial skeleton. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 625-635.	3.1	35
103	The Role of Fibroblast Growth Factor-23 in Cardiorenal Syndrome. <i>Nephron Clinical Practice</i> , 2013, 123, 194-201.	2.3	35
104	Preventing bone loss after renal transplantation with bisphosphonates: We can't but should we?. <i>Kidney International</i> , 2000, 57, 735-737.	2.6	34
105	Differential regulation of receptor-stimulated cyclic adenosine monophosphate production by polyvalent cations in MC3T3-E1 osteoblasts. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 789-799.	3.1	34
106	Role of Fibroblast Growth Factor-23 in Innate Immune Responses. <i>Frontiers in Endocrinology</i> , 2018, 9, 320.	1.5	34
107	Survival Advantage in Black Versus White Men With CKD: Effect of Estimated GFR and Case Mix. <i>American Journal of Kidney Diseases</i> , 2013, 62, 228-235.	2.1	33
108	Uremic Tumoral Calcinosis: Preliminary Observations Suggesting an Association With Aberrant Vitamin D Homeostasis. <i>American Journal of Kidney Diseases</i> , 1991, 18, 706-710.	2.1	32

#	ARTICLE	IF	CITATIONS
109	Aluminum is a weak agonist for the calcium-sensing receptor. <i>Kidney International</i> , 1999, 55, 1750-1758.	2.6	32
110	Evidence for FGF23 Involvement in a Bone-Kidney Axis Regulating Bone Mineralization and Systemic Phosphate and Vitamin D Homeostasis. <i>Advances in Experimental Medicine and Biology</i> , 2012, 728, 65-83.	0.8	30
111	Cloning and Characterization of the Proximal Murine <i>Phex</i> Promoter. <i>Endocrinology</i> , 2001, 142, 3987-3995.	1.4	29
112	Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β -blocker treatment. <i>FASEB Journal</i> , 2016, 30, 994-1001.	0.2	29
113	Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. <i>Journal of Clinical Investigation</i> , 2002, 109, 1361-1371.	3.9	29
114	Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E826-E834.	1.8	28
115	A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. <i>Science Signaling</i> , 2016, 9, ra113.	1.6	27
116	Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 69-80.	3.0	26
117	Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells. <i>Molecular Pharmacology</i> , 2019, 95, 563-572.	1.0	26
118	FGF-23 Deficiency Impairs Hippocampal-Dependent Cognitive Function. <i>ENeuro</i> , 2019, 6, ENEURO.0469-18.2019.	0.9	24
119	A Systems Biology Preview of the Relationships Between Mineral and Metabolic Complications in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2013, 33, 130-142.	0.6	22
120	Activation of FGF-23 Mediated Vitamin D Degradative Pathways by Cholecalciferol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1830-E1837.	1.8	22
121	Multiple faces of fibroblast growth factor-23. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 333-342.	1.0	22
122	Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1108-1116.	2.1	21
123	Osteoblast calcium-sensing receptor has characteristics of ANF/7TM receptors. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 1081-1092.	1.2	20
124	Predictors of Short-Term Changes in Serum Intact Parathyroid Hormone Levels in Hemodialysis Patients: Role of Phosphorus, Calcium, and Gender ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3860-3866.	1.8	19
125	Hyperphosphatemia in end-stage renal disease. <i>Advances in Chronic Kidney Disease</i> , 2002, 9, 184-192.	2.2	19
126	Calcyclin Mediates Serum Response Element (SRE) Activation by an Osteoblastic Extracellular Cation-Sensing Mechanism. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1825-1833.	3.1	19

#	ARTICLE	IF	CITATIONS
127	Unmasking the Osteoinductive Effects of a G-Protein-Coupled Receptor (GPCR) Kinase (GRK) Inhibitor by Treatment With PTH(1-34). <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1661-1670.	3.1	19
128	Elevated FGF23 Levels Are Associated with Impaired Calcium-Mediated Suppression of PTH in ESRD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E57-E64.	1.8	19
129	Computationally identified novel agonists for GPRC6A. <i>PLoS ONE</i> , 2018, 13, e0195980.	1.1	19
130	Developmental regulation of osteocalcin expression in MC3T3-E1 osteoblasts: Minimal role of the proximal E-box cis-acting promoter elements. <i>Journal of Cellular Biochemistry</i> , 1997, 65, 11-24.	1.2	18
131	Inducible expression of <i>Runx2</i> results in multiorgan abnormalities in mice. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 653-665.	1.2	18
132	Continuous arteriovenous hemodialysis: Effect of dialyzer geometry. <i>Kidney International</i> , 1992, 42, 448-451.	2.6	17
133	Parathyroid-specific interaction of the calcium-sensing receptor and $G\hat{1}\pm q$. <i>Kidney International</i> , 2008, 74, 1548-1556.	2.6	17
134	Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. <i>Kidney International</i> , 2005, 68, S24-S28.	2.6	16
135	Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease. <i>Diagnostics</i> , 2018, 8, 71.	1.3	15
136	Role of GPRC6A in Regulating Hepatic Energy Metabolism in Mice. <i>Scientific Reports</i> , 2020, 10, 7216.	1.6	15
137	RUNX2 mutations in Chinese patients with cleidocranial dysplasia. <i>Mutagenesis</i> , 2009, 24, 425-431.	1.0	13
138	Equivalency of various methods for estimating osteoid seam width. <i>Journal of Bone and Mineral Research</i> , 1989, 4, 671-677.	3.1	12
139	Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders. <i>Current Molecular Biology Reports</i> , 2019, 5, 75-85.	0.8	11
140	Humanized GPRC6AKGKY is a gain-of-function polymorphism in mice. <i>Scientific Reports</i> , 2020, 10, 11143.	1.6	11
141	Explaining Divergent Observations Regarding Osteocalcin/GPRC6A Endocrine Signaling. <i>Endocrinology</i> , 2021, 162, .	1.4	11
142	Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new. <i>Journal of Clinical Investigation</i> , 2013, 123, 542-3.	3.9	11
143	Mutations in the COL1A2 gene of type I collagen that result in nonlethal forms of osteogenesis imperfecta. <i>American Journal of Medical Genetics Part A</i> , 1993, 45, 228-232.	2.4	10
144	Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial. <i>Kidney International Reports</i> , 2018, 3, 897-904.	0.4	10

#	ARTICLE	IF	CITATIONS
145	Oral versus intravenous calcitriol. <i>Current Opinion in Nephrology and Hypertension</i> , 1995, 4, 307-312.	1.0	9
146	Calcitriol administration in end-stage renal disease: intravenous or oral?. <i>Pediatric Nephrology</i> , 1996, 10, 331-336.	0.9	9
147	RNA interference and its application in bone-related diseases. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 817-821.	1.0	9
148	Novel Treatments from Inhibition of the Intestinal Sodium-Hydrogen Exchanger 3. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 411-420.	0.8	9
149	Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?. <i>Nephrology News & Issues</i> , 2009, 23, 33-4, 36-7.	0.1	9
150	ASARM mineralization hypothesis: A bridge too far?. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 692-694.	3.1	7
151	Chronic Kidney Disease and Diabetes Mellitus Predict Resistance to Vitamin D Replacement Therapy. <i>American Journal of the Medical Sciences</i> , 2013, 345, 314-320.	0.4	7
152	Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs. <i>International Journal of Nephrology and Renovascular Disease</i> , 2008, 1, 5.	0.8	6
153	Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 337-339.	2.0	5
154	Osseous Complications of Renal Transplantation. <i>Seminars in Dialysis</i> , 1996, 9, 353-359.	0.7	4
155	Aluminum-associated bone disease: What's in a name?. <i>Journal of Bone and Mineral Research</i> , 1986, 1, 389-390.	3.1	4
156	Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115877.	1.4	3
157	Hollow-Fiber versus Parallel-Plate Dialyzers in Continuous Arteriovenous Hemodialysis. <i>Seminars in Dialysis</i> , 1993, 6, 229-231.	0.7	2
158	FGF23/Klotho New Regulators of Vitamin D Metabolism. , 2011, , 747-761.		1
159	Bone Disorders in Chronic Kidney Disease. , 2014, , 476-487.		1
160	Bone Disorders in Chronic Kidney Disease. , 2009, , 487-498.		1
161	Introduction: Emerging therapies derived from the molecular pathogenesis of secondary hyperparathyroidism in ESRD patients. <i>Advances in Chronic Kidney Disease</i> , 2002, 9, 153-158.	2.2	1
162	Clinical Applications of Parathyroid Hormone Immunoassays in Patients with End Stage Renal Disease. <i>Seminars in Dialysis</i> , 1993, 6, 305-311.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Management of Calcium and Bone Disease in Renal Patients. , 2013, , 3073-3086.		0
164	Letter to the Editor: "Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH" Endocrinology, 2018, 159, 3655-3656.	1.4	0
165	FGF-23 Counter-Regulatory Hormone for Vitamin D Actions on Mineral Metabolism, Hemodynamics, and Innate Immunity. , 2018, , 871-884.		0
166	Management of Calcium and Bone Disease in Renal Patients. , 2008, , 2671-2679.		0
167	Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. Development (Cambridge), 2012, 139, e1308-e1308.	1.2	0
168	Role of GPRC6A in Regulating Hepatic Energy Metabolism. SSRN Electronic Journal, 0, , .	0.4	0
169	Calcitriol administration in end-stage renal disease: intravenous or oral?. Pediatric Nephrology, 1996, 10, 331-336.	0.9	0